Investment Banking

NOBLE Capital Markets's investment banking team has a singular focus: to exceed our client's expectations by providing the appropriate advice and execution necessary for efficient capital raising, mergers & acquisitions advisory and capital markets support. We leverage our fundamental sector research expertise in healthcare, natural resources, transportation & logistics, technology, media and telecom, along with our firm's three-decade history of capital markets acumen, in the creation of a customized solution for our clients.

Our investment banking team, together with our well-recognized equity research analysts and the equity capital markets group, provide our clients with fundamental capital markets advisory and support - prior, during and most importantly, after a transaction.

IB Services

NOBLE’s investment banking team works closely with the management and Board of our corporate clients to fully understand operational and financial objectives. With this knowledge our banking team will develop an efficient and effective advisory program which offers a variety of services including:

  • Mergers & Acquisitions (Buy and Sell-Side)
  • Restructuring & Recapitalizations
  • Sale or Divestitures
  • Valuations Services; Purchase Price Allocation – Goodwill Impairment – FV Measurement
  • Fairness Opinions

NOBLE’s investment banking team can achieve transactional success for our clients by tapping into our resident expertise in our research verticals, and through our long-standing relationships with leading institutional investors. NOBLE Capital Markets is routinely involved in the following Corporate Finance transactions:

  • Initial Public Offerings (IPOs)
  • Alternative Public Offerings (APOs)
  • Follow-on Offerings
  • Private Placement in Public Companies (PIPE's)
  • Private Placements in Private Companies
  • At The Market Transactions (ATMs)

Merchant Banking

Our Principal Investment focus is primarily on private and small-cap public ($10mill to $50mill market caps) companies in industries within NOBLE's research verticals. Investments are made directly by NOBLE and its affiliates and may also involve syndicate participants. We work to identify those companies with game-changing or superior products and technologies that have management teams with proven track-records of success. Noble structures investments to meet a company's capital needs whether its growth capital, liquidity or debt repayment. Capital commitment ranges from $200k to $2million principal and $2million above with syndicate.

The scope of our Merchant Banking activities includes:

  • Targeting domestic companies within our areas of focus and expertise
  • Analyzing a company's opportunities and assessing its risks within their respective industry
  • Structuring, negotiating and executing the transaction
  • Work in assessing the appropriate time and manner in which to harvest the investment

Post Transaction Support:
NOBLE's Merchant Banking Team works continuously with our portfolio companies to assist the management team and Board of Directors to create value and grow their businesses to facilitate long-term shareholder value. Through our extensive sector research coverage, institutional investor non-deal road shows, equity conferences and market making, we blend a powerful mix of capital markets acumen to procure success.

Transactions

NOBLE's Investment banking team has, on average, more than 25 years' experience in the industry. Transactions drive our business. Building a solid foundation of mutual respect and trust with our customers drives transactions. Here is a selection of some of the companies we've helped over the years.

Investment Banking Team

Rani Selwanes

Senior Managing Director, Head of Investment Banking

Department:
Investment Banking

E: rselwanes@noblecapitalmarkets.com
T: (561) 912-1734

Rani is a relentless big picture thinker, adept on the world stage delivering creative and bespoke award-winning deals in the Sovereign, Financial Institutions, Oil & Gas, Petrochemicals, Infrastructure, TMT, F&B/FMCG and Consumer sectors. With broad transaction experience in North America, 10 MENA, 5 European and 4 Asian countries. Rani is comfortable in building shareholder value in established and emerging markets.

With over three decades of experience in financial services and investment banking, Rani leads Noble’s advisory and capital raising businesses. Prior to this, he was Managing Director & Head of Investment Banking with NBK Capital for 15 years. Rani firstly originated and led the NBK Capital Investment Banking platform. His leadership enabled acquisition of 80% overall market share, with deal volume exceeding $120B and expanding operations across the MENA region.

He has advised boards and C-suite teams on changing global market landscapes and pushed for acquisitions to drive inorganic growth and generate operating and financial synergies to enhance corporate performance. In concert with his hands-on leadership career, Rani’s engagements at Board/Committee level have focused upon complex financial matters and governance.

As an emerging market expert, he is a featured commentator for CNBC Arabia, Reuters and Bloomberg News networks. Moreover, Rani was a featured speaker on numerous occasions for the Trade and Export Finance, Euromoney, Petroleum Economist, Gulf Bond and Sukuk Association and CME LIBOR Transition conferences across the globe.

Rani has an MBA with high distinction from Fordham University Gabelli School of Business, and a Bachelor of Science from New York University Leonard N. Stern School of Business. He is a Graduate of Executive Programs from IMD in Switzerland, fluent in English and Arabic, and conversational in Spanish and French.

Rani Selwanes, Senior Managing Director, Head of Investment Banking

Nathan Cali

Managing Director, Head of Healthcare Investment and Merchant Banking

Department:
Investment Banking
Healthcare

E: ncali@noblelsp.com
T: (561) 994-5723
VCard: Nathan Cali

Nathan Cali has more than 14 years of combined healthcare, biotechnology and pharmaceutical experience. Mr. Cali was previously a sell-side analyst for 9 years with expertise and publications cover many areas of biotechnology, specialty pharmaceuticals (branded and generics), medical devices, and regenerative medicine. He has been quoted in most business journals including Reuters, BioMed Reports and the Washington Business Journal. Mr Cali is the co-founder of Variant Pharmaceuticals an early stage biotechnology company advancing orphan drugs for the treatment of renal diseases. He is currently a Committee Member at the Moffitt Cancer Center for Commercialization and a member of the Development Board of Palm Beach County. Mr. Cali started his career in healthcare at Andrx Corporation, a biotechnology and specialty pharmaceuticals company known for its expertise in the development of controlled-release drugs. Mr. Cali was a corporate manager dealing in finance, state taxation, corporate governance, patents, drug distribution and business development for the biotechnology firm. Andrx was purchased by Watson Pharmaceuticals in 2006 for $2.0 billion in cash. Prior to joining NOBLE, Mr. Cali gained investment experience as a portfolio account analyst/manager at Franklin Templeton Investments. Mr. Cali holds a B.S. in Finance from The Florida State University and an M.B.A. in Finance from Nova Southeastern University. Nathan also currently holds series 7, 79, 86, and 87 FINRA designations.

Nathan Cali, Managing Director, Head of Healthcare Investment and Merchant Banking

Christopher Ensley

Managing Director, Investment Banking

Department:
Investment Banking

E: censley@noblecapitalmarkets.com
T: (212) 863-3227
LinkedIn: Christopher Ensley

Christopher Ensley is a Managing Director of technology, media & telecom (TMT) investment banking at NOBLE Capital Markets where he focuses on capital raising, mergers and acquisition advisory and valuation opinions for clients. During his tenure on Wall Street, Mr. Ensley has participated in over $16B in transactions. Prior to NOBLE, Mr. Ensley was a TMT investment banker at Coady Diemar Partners, a boutique investment bank in NYC. Prior to Coady Diemar, Mr. Ensley was a Managing Director in the equity research department at Bear Stearns. While at Bear Stearns, Mr. Ensley was a member of the #1 rated broadcast equity research team for six straight years (2002-2007). Mr. Ensley was a Vice President of equity research covering the broadcast sector at Lazard. He began his Wall Street career as an equity research analyst at Salomon Brothers where he covered the tower industry in addition to the broadcasting industry. He received an MBA from Vanderbilt University and a BA from the College of William & Mary.

Christopher Ensley, Managing Director, Investment Banking

Wolfgang Stoiber, MD, MBA

Senior Advisor, Noble Life Science Partners division

Department:
Investment Banking

E: wstoiber@noblelsp.com
T: +49 177 7230152 (EU)
M: +1 978 697 9753 (USA)

Prior to joining Noble, Dr. Stoiber was a co-founder and partner of JSB-Partners. He has more than 30 years of experience as a physician, pharmaceutical industry executive, and investment banker. Dr. Stoiber has advised numerous companies, closing transactions with a cumulative value of more than $2.5 billion.

Before co-founding JSB-Partners, he was a partner at MPM Capital, where he built the firm’s transatlantic business, initiating and managing a number of cross-border transactions with pharmaceutical and biotechnology companies. Prior to MPM he led F. Hoffmann-LaRoche’s Austrian and French pharmaceutical divisions.

Following Dr. Stoiber’s medical and clinical training, his career at Roche began in the organization’s medical marketing division and continued in its marketing and sales operations.

He contributed to the creation of a number of companies, including Therascope, AC Immune, and PNB. Dr. Stoiber previously served on the board of directors of Therascope AG (later Alantos, now Amgen), GPC Biotech AG, and East Pharma Ltd.

Dr. Stoiber earned an MD, Magna Cum Laude, from the University of Munich and an MBA from the Wharton School at the University of Pennsylvania.

Wolfgang Stoiber, MD, MBA, Senior Advisor, Noble Life Science Partners division

Francisco Penafiel

Managing Director, Operations and Investment Banking

Department:
Investment Banking

E: fpenafiel@noblecapitalmarkets.com
T: (561) 994-5740
VCard: Francisco Penafiel

Francisco Penafiel joined NOBLE Capital Markets in 2002 after earning his Master of Science in Economics, with concentrations in Finance and International Economics from Florida Atlantic University. He obtained his undergraduate degree from Escuela Superior Politecnica in Ecuador, where he double-majored in Statistics and Computing Science. Prior to joining the investment banking department at Noble in 2011, Francisco was part of NOBLE's research department, working as a supervisory analyst and equity research analyst covering the enterprise/infrastructure software and business services industries. Other responsibilities included portfolio managing, computer modeling analysis and statistical review. He is also a member of the Company's Investment Policy Committee. Francisco holds various FINRA licenses and is a candidate in the CFA program.

Francisco Penafiel, Managing Director, Operations and Investment Banking